STAT NewsOriginal article
STAT+: Amylyx endocrine drug succeeds in pivotal study
Phase 3positiveavexitidePositive
AI Analysis
Summary
Amylyx's avexitide met its Phase 3 pivotal trial primary endpoint, achieving a 55% reduction in serious low blood sugar events in patients with post-bariatric hypoglycemia compared to control.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
55% reduction in the rate of serious low blood sugar events compared with control
Importance:7/10
Sentiment:
0.85
Phase 3endocrinehypoglycemiapivotal trialpositive data
Read the original article
Published by STAT News on August 18, 2026 11:01 AM